



Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



Ref: ISLL:CH:2011:

17th February, 2011

To: All the Stock Exchanges


Sub: Pursuant to Clause 36 of the Listing Agreement.

Dear Sir,

Pursuant to clause 36 of the Listing Agreement, please find enclosed herewith a Press Release on the latest News Item of the Company for your information and record please.

Thanking you

Yours faithfully,
for IND-SWIFT LABORATORIES LTD.


PARDEEP VERMA
COMPANY SECRETARY

Encl: as above





Ind-Swift Laboratories Limited

(A Recognised Export House)

Regd. Office : S.C.O. 850, Shivalik Enclave, NAC, Manimajra, Chandigarh - 160 101
Phones : ++ 91 - 172-2730503, 2730920, Fax + + 91 - 172 - 2730504, 2736294
E-mail : info@indswiftlabs.com Website : www.indswiftlabs.com



Ind-Swift Laboratories gets PMDA Approval for Pioglitazone and Risedronate Sodium from Govt of Japan

Chandigarh, February 17, 2011: Pharma major Ind-Swift Laboratories Limited got the PMDA approval (Pharmaceutical & Medical devices Agency) from Government of Japan for **Pioglitazone** and **Risedronate Sodium** to be manufactured at its facilities at Derabassi (Punjab). With this achievement it has become the first Indian company to get Japanese Government approval without any observations. This is a significant development in the company's history as it is aiming at huge exports to Japan.

Speaking on the achievement Mr. N.R. Munjal Vice Chairman cum Managing, Director said, "The company has high regulatory standards where its facilities are already approved by USFDA/TGA/COS/KFDA and with this approval for **Pioglitazone** which is an anti diabetic drug with market size worth US\$ 2.8 bn and **Risedronate Sodium** a drug for Osteoporosis with market size worth US\$ 1.6bn, the company is aiming at capturing 15-20 per cent of the market share of these products by 2013."

It is for the first time that a large number of drugs patented by Japanese companies are going off patent. With the healthcare market size of USD 350 bn and only USD 13 bn worth of pharma product imports, Japan is a promising market for Indian Pharma manufacturers. The rapid pace of population aging and associated high healthcare expenditure is also increasing the popularity of generics in Japan. Japan's pharma imports from India are currently less than USD 10 mn and these factors are likely to boost export prospects. "We are in the advance stage of negotiations to supply commercial quantities of these products to the Japanese Market and the free trade pact between India and Japan will further strengthen company's export revenues", Mr. Munjal added.

The Company has already filed 4 DMFs in Japan including that of Atorvastatin a 12bn Market drug. PMDA approval for these products is expected shortly, that will take the total approved products to six. ISLL has also filed 302 DMFs so far with various regulatory Authorities including 4 DMFs filed in Japan.

Company clocked a turnover of Rs. 714.32 crores during the nine months ended 31st December, 2010 as against Rs 579.84 crores in similar period in 2009. Company earned a Net profit of Rs 61.22 crores in first nine months against the Net Profit of Rs. 57 crores earned in Financial year ended March, 2010.

